Literature DB >> 16186785

The impact of obesity on the incidence and treatment of gynecologic cancers: a review.

Susan C Modesitt1, John R van Nagell.   

Abstract

UNLABELLED: Sixty-five percent of the adult population in the United States is overweight and 30% of the population is obese. There is mounting evidence that obesity is a risk factor for gynecologic cancers and may also adversely impact survival. The objectives of this review were to systematically evaluate and discuss the impact of overweight and obesity on endometrial, ovarian, and cervical cancer incidence and to review the data on the impact of obesity on treatment of these same gynecologic cancers. A PUBMED literature search was performed to identify articles in the English language that focused on the impact of obesity on cancer incidence and treatment. References of identified articles were also used to find additional related articles. Obesity profoundly increases the incidence of endometrial cancer, predominantly through the effects of unopposed estrogen. Although the data are less compelling in ovarian and cervical cancer, obesity may modestly increase the incidence of premenopausal ovarian cancer and might potentially increase cervical cancer incidence, perhaps as a result of the impact on glandular cancers or decreased screening compliance. Obese women with cancer have decreased survival; this may be disease-specific, the result of comorbid illnesses, or response to treatment. Obese women have increased surgical complications, may also have increased radiation complications, and there is no current consensus regarding appropriate chemotherapy dosing in the obese patient. Obesity is a serious health problem with significant effects on the incidence and treatment of the gynecologic malignancies. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING
OBJECTIVES: After completion of this article, the reader should be able to summarize the clear evidence that obesity is a risk factor for many cancers, including gynecologic malignancies; describe the role of unopposed estrogen in gynecologic cancers; and explain that obese women overall have a poorer survival rate when afflicted with cancer.

Entities:  

Mesh:

Year:  2005        PMID: 16186785     DOI: 10.1097/01.ogx.0000180866.62409.01

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  41 in total

1.  Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  L M Hess; R Barakat; C Tian; R F Ozols; D S Alberts
Journal:  Gynecol Oncol       Date:  2007-08-06       Impact factor: 5.482

2.  Factors affecting survival among women with breast cancer in Hawaii.

Authors:  Gertraud Maskarinec; Ian Pagano; Galina Lurie; Erin Bantum; Carolyn C Gotay; Brian F Issell
Journal:  J Womens Health (Larchmt)       Date:  2011-01-31       Impact factor: 2.681

Review 3.  The Impact of Obesity on Surgical Outcome in Endometrial Cancer Patients: A Systematic Review.

Authors:  Olubunmi Orekoya; Marsha E Samson; Tushar Trivedi; Shraddha Vyas; Susan E Steck
Journal:  J Gynecol Surg       Date:  2016-06-01

4.  Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.

Authors:  Elisa V Bandera; Valerie S Lee; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

5.  Adiponectin receptor expression in human malignant tissues.

Authors:  Sharon H Chou; Sofia Tseleni-Balafouta; Hyun-Seuk Moon; John P Chamberland; Xiaowen Liu; Nikolaos Kavantzas; Christos S Mantzoros
Journal:  Horm Cancer       Date:  2010-06       Impact factor: 3.869

6.  Dosing of chemotherapy in obese and cachectic patients: results of a national survey.

Authors:  Helena Anglada-Martínez; Gisela Riu-Viladoms; Fernando do Pazo-Oubiña; Gloria Molas-Ferrer; Irene Mangues-Bafalluy; Carles Codina-Jané; Natàlia Creus-Baró
Journal:  Int J Clin Pharm       Date:  2014-04-27

7.  Dilator Use After Vaginal Brachytherapy for Endometrial Cancer: A Randomized Feasibility and Adherence Study.

Authors:  Alexandra Hanlon; William Small; Jonathan Strauss; Lilie L Lin; Laura Hanisch; Liming Huang; Jinbing Bai; Jessica Wells; Deborah Watkins Bruner
Journal:  Cancer Nurs       Date:  2018 May/Jun       Impact factor: 2.592

8.  Diabetes mellitus and risk of endometrial cancer: a meta-analysis.

Authors:  E Friberg; N Orsini; C S Mantzoros; A Wolk
Journal:  Diabetologia       Date:  2007-05-03       Impact factor: 10.122

9.  Knowledge of obesity and its impact on reproductive health outcomes among urban women.

Authors:  Eden R Cardozo; Tanaka J Dune; Lisa M Neff; Maureen E Brocks; Geraldine E Ekpo; Randall B Barnes; Erica E Marsh
Journal:  J Community Health       Date:  2013-04

10.  The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival.

Authors:  Koji Matsuo; Michael J Gray; Dong Yun Yang; Sucheta A Srivastava; Prem B Tripathi; Laura A Sonoda; Eun-Jeong Yoo; Louis Dubeau; Amy S Lee; Yvonne G Lin
Journal:  Gynecol Oncol       Date:  2012-11-28       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.